Tamoxifen is a selective estrogen receptor modulator used for adjuvant treatment of luminal (estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive) breast cancer (BC) subtypes. This evidence concerns the gene ESR1 and breast carcinoma.